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Access to the complete human genome sequence as well as to the complete sequences of pathogenic organisms provides 
information that can result in an avalanche of therapeutic targets. Structure-based design is one of the first techniques to be 
used in drug design. Structure based design refers specifically to finding and complementing the 3D structure (binding 
and/or active site) of a target molecule such as a receptor protein. The aim of this review is to give an outline of studies in 
the field of structure based drug design that has helped in the discovery process of new drugs. The emphasis will be on 
comparative/homology modeling. 
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Background: 
Discussion of the use of structural biology in drug 
discovery began over 35 years ago, with the advent of 
knowledge of the 3D structures of globins, enzymes and 
polypeptide hormones. Early ideas in circulation were the 
use of 3D structures to guide the synthesis of ligands of 
haemoglobin to decrease sickling or to improve storage of 
blood [1], the chemical modification of insulins to increase 
half-lives in circulation [2] and the design of inhibitors of 
serine proteases to control blood clotting. [3] An early and 
bold venture was the UK Wellcome Foundation 
programme focussing on haemoglobin structures 
established in 1975. [4] However, X-ray crystallography 
was expensive and time consuming. It was not feasible to 
bring this technique ‘in-house’ into industrial laboratories, 
and initially the pharmaceutical industry did not embrace it 
with any real enthusiasm. In time, knowledge of the 3D 
structures of target proteins found its way into thinking 
about drug design. Although, in the early days, structures of 
the relevant drug targets were usually not available directly 
from X-ray crystallography, comparative models based on 
homologues began to be exploited in lead optimization in 
the 1980s. [5] An example was the use of aspartic protease 
structures to model renin, a target for antihypertensives. [6] 
It was recognized that 3D structures were useful in defining 
topographies of the complementary surfaces of ligands and 
their protein targets, and could be exploited to optimize 
potency and selectivity. [7] Eventually, crystal structures of 
real drug targets became available; AIDS drugs, such as 
Agenerase and Viracept, were developed using the crystal 
structure of HIV protease [8] and the flu drug Relenza was 
designed using the crystal structure of neuraminidase. [9] 
There are now several drugs on the market that originated 
from this structure-based design approach; [10] list >40 
compounds that have been discovered with the aid of 
structure-guided methods and that have entered clinical 
trials. The structure-based design methods used to optimize 
these leads into drugs are now often applied much earlier in 
the drug discovery process. Protein structure is used in 
target identification and selection (the assessment of the 
‘druggability’ or tractability of a target), in the 
identification of hits by virtual screening and in the 
screening of fragments. Additionally, the key role of 
structural biology during lead optimization to engineer 
increased affinity and selectivity into leads remains as 
important as ever. 
 
Description: 
Common drug targets 
The introduction of genomics, proteomics and 
metabolomics has paved the way for biology-driven 
process, leading to plethora of drug targets. The list of 
potential drug targets encoded in a genome includes most 
natural choice of virulent genes and species-specific genes. 
Other options include targeting RNA, enzymes of the 
intermediary metabolism, systems for DNA replication, 
translation apparatus or repair and membrane proteins 
(Figure 1).  
 
Species-specific genes as drug targets 
Comparative analysis of the complete genome sequences of 
bacterial pathogens available in the public databases offers 
the first insights into drug discovery approaches of the near 
future.  [11] An interesting approach to the prediction of 
potential drug targets designated as the differential genome 
display has been proposed by Bork and co-workers. [12] 
This approach relies on the fact that genome of parasitic 
microorganisms are generally much smaller and code for 
fewer proteins than the genomes of free-living organisms. 
The genes that are present in the genome of a parasitic 
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living bacterium, are therefore likely to be important for 
pathogenecity and can be considered as potential drug 
targets. Exhaustive comparison of H.influenzae and E.coli 
gene products identified 40 H.influenzae genes that have 
been exclusively found in pathogens and thus constitute 
potential drug targets.     
 
Nucleic acid as drug targets 
Nucleic acids are the repository of genetic information. 
DNA itself has been shown to be the receptor for many 
drugs used in cancer and other diseases. These work 
through a variety of mechanisms including chemical 
modification and cross linking of DNA (cisplatin) or 
cleavage of the DNA (bleomycin). Much work either by 
intercalation of a polyaromatic ring system into the double 
stranded helix (actinomycin D, ethidium) or by binding to 
the major and minor grooves of DNA (e.g., netropsin) 
(Figure 2) [13] has been reported. DNA has been shown to 
be the target for chemotherapy with efforts to design 
sequence-specific reagents for gene therapy. 
 
RNA as drug target 
Recent advances in the determination of RNA structure and 
function have led to new opportunities that will have a 
significant impact on the pharmaceutical industry. RNA, 
which, among other functions, serves as a messenger 
between DNA and proteins, was thought to be an entirely 
flexible molecule without significant structural complexity. 
However, recent studies have revealed a surprising 
intricacy in RNA structure. This observation unlocks 
opportunities for the pharmaceutical industry to target RNA 
with small molecules. Perhaps more importantly, drugs that 
bind to RNA might produce effects that cannot be achieved 
by drugs that bind to proteins. [14] Proof of the principle 
has already been provided by success of several classes of 
drugs obtained from natural sources that bind to RNA or 
RNA-protein complexes. 
 
Membranes as drug targets  
Membranes are significant structural elements, both in 
defining the boundaries of a cell as well as providing 
interior compartments within the cell associated with 
particular functions. Cell membranes themselves can also 
act as targets for molecular recognition. An understanding 
of the structural and dynamic functions of the membranes 
(e.g., plasma membranes and intercellular membranes) may 
add to a more rational design of drug molecules with 
improved permeation characteristics or specific membrane 
effects. Many general anesthetics are believed to work by 
their physical effects when dissolved in membranes. 
Several classes of antibiotics like gramicidin A, antifungals 
like alamethicin and toxins such as mellitin found in bee 





Proteins as drug targets  
Proteins continue to assume significant attention from the 
pharmaceutical and biotechnology industries as a valuable 
source of potential drug targets. [15] Proteins provide the 
critical link between genes and disease, and as such are the 
key to the understanding of basic biological processes 
including disease pathology, diagnosis, and treatment. 
Researchers have discovered many potential therapeutic 
targets, and there are currently more than 700 products in 
various phases of development. However, translating the 
study of proteins into validated drug targets poses 
substantial challenges. Genome sequences instruct cells on 
how and when to make proteins. The proteins in turn are 
the active players in the cell. Proteins form the machinery 
of cells, allow cells to communicate, and can control 
growth or death of an organism. Because of their role in 
cells, most of the drug targets are proteins. Drugs work by 
binding specifically to a protein. Extensive knowledge 
about the function of a protein can guide the selection of 
targets for pharmaceutical chemists. Studying the complex 
domain of 200,000-300,000 distinct and interactive proteins 
poses substantial challenges. Most target proteins for drug 
development participate in key regulatory steps in the 
human body or in an infectious organism. As such, they 
tend to be present in few copies only and often within 
specific cells. Their isolation and purification using 
traditional preparative biochemical means and in quantities 
required for routine assays has been a formidable 
challenge. This situation has been radically changed by the 
ability to clone and express proteins. Thus many key target 
proteins are now becoming available in sufficient amounts 
to make them amenable not only to biological assays but 
also to NMR studies in solution and to crystallization for 
X-ray analysis. The number of protein structures solved 
using X-ray or NMR has begun to rise sharply and more 
than 40,000 protein three-dimensional structures have been 
deposited in the Protein Data Bank [16] till date (December 
2006). Various classes of proteins can be categorized as 
potential drug targets. 
 
Small molecules such as drugs, insecticides or herbicides 
usually exert their effects by binding to protein targets. In 
the past, many of these molecules were found empirically 
with little or no knowledge of the mechanism of action 
involved. In many cases, the targets that are modified by 
these substances were identified in retrospect. Interestingly, 
the majority of drugs currently in use modulate either 
enzymes or receptors, most of them G-protein-coupled 
receptors. 
 
a. Enzymes - The macromolecule responsible for the 
catalysis of biochemical reactions are an obvious target 
when a disease state is associated with production of a 
biologically active species. Enzymes are a classic target for 
therapeutic intervention and numerous well-studied 
examples exist. Bioinformation by Biomedical Informatics Publishing Group                   open access 
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Traditional medicinal chemistry enzyme targets include 
kinases, phosphodiesterases, proteases and phosphotases. 
Some of the examples of drug targeted against enzymes are 
listed in Table 1. 
 
b. Receptor proteins - G-protein–coupled receptors are a 
super family of seven transmembrane spanning proteins 
that are activated by a wide range of extracellular ligands 
and are expressed in virtually all tissues. Signaling through 
these receptors regulates a wide variety of physiological 
processes such as neurotransmission, chemotaxis, 
inflammation, cell proliferation, cardiac and smooth muscle 
contraction as well as visual and chemosensory perception. 
In view of their widespread distribution and importance in 
health and disease, it is not surprising that GPCRs are the 
most successful class of target proteins for drug discovery 
research. [17] 
 
The sequencing of human genome has led to the prediction 
of as many as 1000 GPCRs, of which 400 are non-
chemosensory receptors and can therefore be considered as 
potential drug-targets. [18] It has been estimated that up to 
50 % of all marketed drugs directly target this family of 
receptors [19], some of which are listed in Table 2.          
                                
The goal in developing drugs against the targets listed 
above is often to modulate the function of the human 
protein while the goal in developing drugs against 
pathogenic organisms is total inhibition, leading to the 
death of the pathogen. Antimicrobial drugs should be 
essential to the pathogen, have a unique function in the 
pathogen, be present only in the pathogen, and be able to be 
inhibited by a small molecule. 
                          
The target should be essential, in that it is a part of a crucial 
cycle in the cell, and its elimination should lead to the 
pathogen’s death. The target should be unique: no other 
pathway should be able to supplement the function of the 
target and overcome the presence of the inhibitor. If the 
macromolecule satisfies all the outlined criteria to be a drug 
target but functions in healthy human cells as well as in a 
pathogen, specificity can often be engineered into the 
inhibitor by exploiting structural or biochemical differences 
between the pathogenic and human forms. Finally, the 
target molecule should be capable of inhibition by binding 
of a small molecule. Enzymes are often excellent drug 
targets because compounds are designed to fit within the 
active site pocket. 
 
Structure based drug design 
Drug discovery referred to, as ‘rational’ did not take flight 
until the first structures of the targets were solved. In 1897, 
Ehrlich suggested a theory called the side chain theory 
wherein he proposed that specific groups on the cells 
combine with the toxin. Ehrlich coined these side chains as 
receptors. Structure-based drug design of protein ligands 
has emerged as a new tool in medicinal chemistry. [20] The 
central assumption of structure-based drug design [21] is an 
iterative one as shown in Figure 3 and often proceeds 
through multiple cycles before an optimized lead goes into 
clinical trials. 
 
The first cycle includes the cloning, purification and 
structure determination of the target protein or nucleic acid 
by one of three principal methods: X-ray crystallography, 
NMR or comparative modeling. Using computer 
algorithms, compounds or fragments of compounds from a 
database are positioned into a selected region of the 
structure. 
 
These compounds are scored and ranked based on their 
steric and electrostatic interactions with the target site and 
the best compounds are tested further with biochemical 
assays. In the second cycle, structure determination of the 
target in complex with a promising lead from the first 
cycle, one with at least micromolar inhibition in vitro, 
reveals sites on the compound that can be optimized to 
increase potency. Additional cycles include synthesis of the 
optimized lead, structure determination of the new target: 
lead complex, and further optimization of the lead 
compound. 
 
After several cycles of the drug design process, the 
optimized compounds usually show marked improvement 
in binding, and often, specificity for the target. 
 
Evaluating a structure for structure based drug design 
Once a target has been identified, it is necessary to obtain 
accurate structural information. There are three primary 
methods for structure determination that are useful for 
drug-design: X-ray crystallography, NMR, and homology 
modeling. 
 
High-resolution crystal structures are the most common 
desired source of structural information for drug design, 
particularly for proteins that range in size from a few amino 
acids to 998kD. [22] Another advantage of crystallography 
is that ordered water molecules are visible in the 
experimental data and are often useful in drug design. A 
crystal structure should be evaluated for the resolution of 
the diffracted amplitudes (often simply called resolution); 
reliability, or R factors; coordinate error; temperature 
factors; and chemical correctness. Typically, crystal 
structures determined with data extending below 2.5 A
0   are 
acceptable for drug design purposes since they have a high 
data to parameter ratio, and the placement of residues in the 
electron density map is unambiguous. The R factor and 
Rfree reported for a model are measures for the correlation 
between the model and experimental data. The Rfree value 
should be below 28% and ideally below 25%, and the R 
factor should be well below 25% in order to use the 
structure in drug design. If the only structure available for a 
particular target does not meet the resolution or R factor Bioinformation by Biomedical Informatics Publishing Group                   open access 
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criteria, drug design projects can still be considered, but the 
results should be judged carefully. 
 
Structures determined by nuclear magnetic resonance, 
using a concentrated protein or nucleic acid in solution are 
also valuable sources for drug design. [23] Since the target 
is in solution it is sometimes possible to interpret the 
dynamics of the target from the data. If no experimentally 
determined structure is available, a homology model can be 
used for drug design. [24, 25]  To evaluate a homology 
model, SWISS MODEL outputs a confidence factor per 
residue that reflects the amount of structural information 
used to create that portion of the model. 
 
Using the structural information obtained through the 
above techniques, the structure is then prepared for drug 
design programs. 
 
Present  state of the art: Computer-aided drug design 
Given the vast size of organic chemical space [26], drug 
discovery cannot be reduced to a simple “synthesize and 
test” drudgery. There is an urgent need to identify and/ or 
design drug-like molecules [27] from the vast expanse of 
what could be synthesized. In silico methods have the 
potential to reduce both time and cost in developing 
suggestions on drug/ lead-like molecules. Computational 
tools have the advantage for delivering new lead candidate 
more quickly and at lower cost. Drug discovery in the 21
st 
century is expected to be different in at least two distinct 
ways: development of individualized medicine departing 
from genomic information and extensive use of in silico 
simulations to facilitate target identification, structure 
prediction and lead/drug discovery. The expectations from 
computational methods for reliable and expeditious 
protocols for developing suggestions on potential leads are 
continuously on the increase. Several conceptual and 
methodological concerns remain before an automation of 
drug design in silico could be contemplated.  
 
Computational methods are needed to exploit the structural 
information to understand specific molecular recognition 
events and to elucidate the function of the target 
macromolecule (Figure 4). This information should 
ultimately lead to the design of small molecule ligands for 
the target, which will block/activate its normal function and 
thereby act as improved drugs.  
 
As structural genomics, bioinformatics, and computational 
power continue to explode with new advances, further 
successes in structure-based drug design are likely to 
follow. Each year, new targets are being identified; 
structures of those targets are being determined at an 
amazing rate, and capability to capture a quantitative 
picture of the interactions between macromolecules and 
ligands is accelerating. 
 
Success of computer-assisted molecular design 
The greatest success of computer-aided structure-based 
drug design to date is the HIV-1 protease inhibitors that 
have been approved by the United States Food and Drug 
Administration and reached the market. [28] There have 
been many successful computer-assisted molecular design 
attempts to involve the use of QSAR to improve activity of 
lead compounds. An example of the success story is that of 
SAR work carried out on antibacterial agent, Norfloxacin 
[29] that showed 6-fluro derivative of norfloxacin being 
500 fold more potent over nalidixic acid. Other examples of 
drugs that were developed using computer –assisted drug 
design include Captopril (antihypertensive), Crixican (anti-
HIV)  [30], Teveten (antihypertensive) [31], Aricept( for 
Alzheimers disease) [32], Trusopt ( for Glaucoma) [30] and 
Zomig ( for migraine). [33] 
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Figure 2: Netropsin molecule. The narrowness of the groove forces the netropsin molecule to sit symmetrically in the 
center, with its two pyrrole rings slightly non-coplanar so that each ring is parallel to the walls of its respective region 
of the groove [13] 
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Figure 4: Potential areas for in silico intervention in drug discovery 
 
Enzyme Drug 
Dihydrofolate reductase  Methotrexate  
HIV-1 protease  Saquinavir, Indinavir 
ACE Captopril 
Neuraminidase Oseltamivir 
Cyclin dependent Kinase(CDKs)  Flavopiridol 
Cyclooxygenase Diclofenac,  Indomethacin 
Thymidylate synthase  Tomudex 
Guanine phosphoribosyltranseferase (GPRT)  Allopurinol 
Inosine5’-monophosphate dehydrogense  Tiazopurin 
 Table 1: Some enzymes as drug targets 
 
GPCR Indication(s)  Drug(s) 
Histamine Allergies,  ulcers  Cimetidine,Ranitidine,Terfenadine 
ß-adrenergic Hypertension,  asthma  Atenolol, Albuterol, Salmeterol 
α-adrenergic Benign  prostatichypertrophy Terazosin  ,  doxazosin 
Dopamine  Psychosis, Parkinson’s   Aripiprazole, Ropinerole 
Serotonin Migraine,  anxiety  Zolmitriptan, clozapine, buspirone 
Opoid  Pain   Butarphanol  
Angiotensin Hypertension    Losartan,  Eprosartan 
Muscarinic acetylcoline  Alzheimer’s disease  Bethanechol, dicyclomine 
Leukotriene   Asthma   Pranlukast  
 Table 2: Some currently marketed drugs that target GPCRs 
 
Utility of Homology Models in the Drug Discovery 
Process 
Advances in bioinformatics and protein modeling 
algorithms, in addition to the enormous increase in 
experimental protein structure information, have aided in 
the generation of databases that comprise homology models 
of a significant portion of known genomic protein 
sequences. Currently, 3D structure information can be 
generated for up to 56% of all known proteins. However, 
there is considerable controversy concerning the real value 
of homology models for drug design. Despite the numerous 
uncertainties that are associated with homology modeling, Bioinformation by Biomedical Informatics Publishing Group                   open access 
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recent research has shown that this approach can be used to 
significant advantage in the identification and validation of 
drug targets, as well as for the identification and 
optimization of lead compounds. Homology model-based 
drug design has been applied to epidermal growth factor-
receptor tyrosine kinase protein [34], Bruton’s tyrosine 
kinase [35], Janus kinase 3 [36] and human aurora 1 and 2 
kinases. [37] In the thesis, focus is on the application of 
homology models to the drug discovery process. 
 _______________________________________________________________________________________________                                          
Conclusion: 
Thus, it can be said that pharmaceutical and biotechnology 
research has undergone great change. Traditionally, the 
crucial impasse in the industry’s search for new drug 
targets was the availability of biological data. Now with the 
advent of human genomic sequence, bioinformatics offers 
several approaches for the prediction of structure and 
function of proteins on the basis of sequence and structural 
similarities. The protein sequenceÆstructureÆfunction 
relationship is well established and reveals that the 
structural details at atomic level help understand molecular 
function of proteins. Impressive technological advances in 
areas such as structural characterization of 
biomacromolecules, computer sciences and molecular 
biology have made rational drug design feasible and 
present a holistic approach.
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